King Pharmaceuticals KG Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $272K-3.2% | $281K+368% | $60K-97.9% | $2.89M— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$12.93M+31.0% | -$18.74M-160% | $31.42M+310% | $7.67M+639% | -$1.42M+9.4% | ||
| —— | —— | —— | —— | -$828.75K+43.4% | ||
| $8.3M+19.2% | $6.96M+6.2% | $6.55M+519% | $1.06M— | $0— | ||
| -$7.03M-7.9% | -$6.52M-51.3% | -$4.31M-225% | -$1.33M— | —— | ||
| -$71.02M-30.8% | -$54.28M-14.9% | -$47.25M-88.3% | -$25.09M— | —— | ||
| -$110.4M-14.8% | -$96.14M-214% | -$30.65M-43.0% | -$21.44M— | —— | ||
| $11.79M+23.7% | $9.53M+27.8% | $7.46M+440% | $1.38M— | —— | ||
| $100.91M+60.7% | $62.79M+313% | $15.19M+108% | $7.31M— | —— | ||
| $28K+33.3% | $21K+16.7% | $18K+1,700% | $1K— | —— | ||
| $1.55M+44.1% | $1.08M+78.0% | $604K+23.3% | $490K— | —— | ||
| —— | —— | —— | —— | —— | ||
| $199.94M+36.1% | $146.95M+40.7% | $104.41M+18.2% | $88.33M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$40M— | —— | ||
| —— | —— | —— | $661K— | —— | ||
| —— | —— | $34.26M+24.3% | $27.56M— | —— | ||
| —— | -$2.81M-33.3% | -$2.11M-50.0% | -$1.41M-100% | -$703.25K— | ||
| —— | $11.34M+33.3% | $8.5M+50.0% | $5.67M+100% | $2.83M— | ||
| —— | $48K+33.3% | $36K+50.0% | $24K+100% | $12K— | ||
| -$3.63M-23.1% | -$2.95M-52.6% | -$1.93M-63.1% | -$1.19M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $8.3M+19.2% | $6.96M+6.2% | $6.55M+519% | $1.06M— | $0— | ||
| —— | -$2.81M-33.3% | -$2.11M-50.0% | -$1.41M-100% | -$703.25K— | ||
| $23K-4.2% | $24K+200% | -$24K— | $0— | —— | ||
| —— | —— | $945K+18.0% | $801K— | —— | ||
| -$12.93M+31.0% | -$18.74M-160% | $31.42M+310% | $7.67M+639% | -$1.42M+9.4% | ||
| -$71.02M-30.8% | -$54.28M-14.9% | -$47.25M-88.3% | -$25.09M— | —— | ||
| —— | —— | —— | —— | -$828.75K+43.4% | ||
| -$10.28M-3.8% | -$9.91M-1,258% | -$730K-685% | -$93K— | —— | ||
| —— | —— | -$5.37M-250% | $3.59M— | —— | ||
| -$7.03M-7.9% | -$6.52M-51.3% | -$4.31M-225% | -$1.33M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $28K+33.3% | $21K+16.7% | $18K+1,700% | $1K— | —— | ||
| $1.55M+44.1% | $1.08M+78.0% | $604K+23.3% | $490K— | —— | ||
| $11.79M+23.7% | $9.53M+27.8% | $7.46M+440% | $1.38M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $100.91M+60.7% | $62.79M+313% | $15.19M+108% | $7.31M— | —— | ||
| —— | —— | $1.23M+84.3% | $668K— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does King Pharmaceuticals generate?
- King Pharmaceuticals (KG) generated -$110.4M in operating cash flow over the trailing twelve months.
- Where does King Pharmaceuticals's cash flow data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
